Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease
|ClinicalTrials.gov Identifier: NCT00088673|
Recruitment Status : Unknown
Verified February 2007 by Bellus Health Inc.
Recruitment status was: Active, not recruiting
First Posted : August 3, 2004
Last Update Posted : February 28, 2007
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease||Drug: 3APS||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||950 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase III Study of the Efficacy and Safety of 3APS in Patients With Mild to Moderate Alzheimer’s Disease|
|Study Start Date :||June 2004|
- The two primary efficacy parameters are the change from baseline to month 18 in the Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog) and the clinical Deterioration Scale Sum of Boxes (CDR-SB) scores.
- The brain volume change from baseline as measured by Magnetic Resonance Imaging will also be assessed.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00088673
Show 67 Study Locations